Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

This post was written by Melanie Riehl BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Check the time stamp on this data. Updated AI-Generated Signals for Global Partners Lp Representing Limited Partner Interests ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Cash position of €10.3 million as of June 30, 2024 Net loss of €8.9 million as of June 30, 2024, comparable to the same period in 2023 Debt limited to a state-guaranteed loan amounting ...

The GLP-developed warehouses were disposed of due to "the stabilised nature of the portfolio, its attractive quality and ...

The company currently has $6.7 billion of major capital projects under construction that should enter commercial service ...

Kepler Capital analyst Aymeric Poulain maintained a Hold rating on Saab AB (0GWL – Research Report) on September 17 and set a price ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...